Symptomatic myopathy during interferon alfa therapy for chronic myelogenous leukemia

TO THE EDITOR
We report an unusual and serious complication in a patient with chronic myeloid leukemia (CML) undergoing alfa-interferon treatment.
A 26-year-old man, suffering from Philadelphia chromosome (Ph)-positive CML, had been treated for 23 months with recombinant interferon alfa (IFN␣), administered at 9 million IU daily. A minor cytogenetic response was obtained in the 12th month of therapy (Ph + 76%). The patient was admitted to our hospital in March 1996, because of the appearance of pharyngodynia, dysphonia, widespread myalgias, dysphagia and symmetric muscle weakness of the extremities. The IFN␣ therapy had been stopped in the previous week because of fever. During the physical examination we noted a deficiency of velum palatinum and hypotrophy of face and tongue muscles, and in addition, a reduction of chest expansion and a reduction of muscular strength. Blood profiles showed increased alanine aminotransferase (ALT) at 867 IU/l (normal Ͻ60), aspartate aminotransferase (AST) 827 IU/l (normal Ͻ63), lactate dehydrogenase (LDH) 2318 IU/l (normal Ͻ460) and creatine kinase (CK) 17039 IU/l (normal Ͻ195) with 98% of striated muscle-type isonzyme. Magnetic resonance imaging of the brain showed no alterations. Electroneurography was also normal. Electromyography showed myopathic abnormalities. Deltoid muscle biopsy showed lymphocytic and monocytic infiltrates, inequality of fiber size and some muscle necrosis areas, suggestive of polymyositis. Rheumatoid factor, serum Creactive protein and antinuclear antibodies were negative. Serum anti-HCV antibodies were also negative. Peripheral blood count was normal without immature peripheral cells and the chronic phase of the disease was confirmed by bone marrow examination.
Respiratory muscle became progressively weaker and because of an increase of Pa CO 2 on the 7th day, the patient was transferred to the intensive care unit for mechanical ventilation, and gastrostomy was required as well due to inability to swallow. The methyl-prednisolone therapy was started at 150 mg daily and plasma exchange was performed for 4 days without any improvement. Although serum CPK returned to normal levels on the 17th day, the recovery of autonomous breathing was achieved only after 12 months, when the patient was discharged from the hospital with a slight muscle weakness of the extremities. The CML was still in its chronic phase and treated with hydroxyurea.
We have described a very serious case of polymyositis, where the level of CK increased to 90 times the normal, Correspondence: A Falcone; Fax: 39 882 411705 Received 9 December 1997; accepted 23 April 1998 although CK concentration is an expression of active disease and a fall is usually paralleled with muscle strength. 1 We observed normal level of CK after 17 days with corticosteroid therapy and a very slow and progressive improvement in muscle strength, on the other hand, the muscle involved was vast. Polymyositis (PM) is not frequently associated with hematology diseases. 2 In our case, the PM was not associated with and did not precede a change of phase of the disease. Immune-mediated complications were also recorded during long-term treatment with IFN␣. 3, 4 PM is a dysimmune condition where the cytotoxic CD8 + T cell and the lymphokines (interleukin-1, tumor necrosis factor ␣ and interferon ␥) secreted by the activated T cells caused myocytotoxicity. 5 IFN␣ influences expression of several cytokines, and in particular, increases the production of TNF␣. 6, 7 IFN␣ could play a role in our case, considering these observations and the resolution of disease without relapses with stopping IFN␣ and immunosuppressive therapy.
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